Literature DB >> 8439501

Neuroblastoma in a transgenic mouse carrying a metallothionein/ret fusion gene.

T Iwamoto1, M Taniguchi, W Wajjwalku, I Nakashima, M Takahashi.   

Abstract

We have recently succeeded in producing transgenic mice carrying a hybrid gene consisting of mouse metallothionein promoter-enhancer and the ret oncogene (MT/ret). (Iwamoto et al., 1991b). A retroperitoneal tumour developed in one of 17 MT/ret transgenic founder mice. Histological analysis revealed that the tumour consisted of undifferentiated neuroblasts and differentiated ganglion cells, the latter of which were strongly positive for neuron specific enolase. Expression of the ret transgene was observed at high levels in RNA from the tumour, but not in those of other normal tissues. In addition, a 100kDa ret protein was detected in the cell lysate of the tumour. Taken together with our previous data, these results suggest a possible role for the ret oncogene in the proliferation of neural crest cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8439501      PMCID: PMC1968281          DOI: 10.1038/bjc.1993.94

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

1.  Characterization of ret proto-oncogene mRNAs encoding two isoforms of the protein product in a human neuroblastoma cell line.

Authors:  T Tahira; Y Ishizaka; F Itoh; T Sugimura; M Nagao
Journal:  Oncogene       Date:  1990-01       Impact factor: 9.867

2.  ret transforming gene encodes a fusion protein homologous to tyrosine kinases.

Authors:  M Takahashi; G M Cooper
Journal:  Mol Cell Biol       Date:  1987-04       Impact factor: 4.272

3.  Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains.

Authors:  M Takahashi; Y Buma; T Iwamoto; Y Inaguma; H Ikeda; H Hiai
Journal:  Oncogene       Date:  1988-11       Impact factor: 9.867

4.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

5.  Specific expression of the ret proto-oncogene in human neuroblastoma cell lines.

Authors:  I Ikeda; Y Ishizaka; T Tahira; T Suzuki; M Onda; T Sugimura; M Nagao
Journal:  Oncogene       Date:  1990-09       Impact factor: 9.867

6.  Deregulated c-fos expression interferes with normal bone development in transgenic mice.

Authors:  U Rüther; C Garber; D Komitowski; R Müller; E F Wagner
Journal:  Nature       Date:  1987 Jan 29-Feb 4       Impact factor: 49.962

7.  Acute leukaemia in bcr/abl transgenic mice.

Authors:  N Heisterkamp; G Jenster; J ten Hoeve; D Zovich; P K Pattengale; J Groffen
Journal:  Nature       Date:  1990-03-15       Impact factor: 49.962

8.  Oncogenicity of the ret transforming gene in MMTV/ret transgenic mice.

Authors:  T Iwamoto; M Takahashi; M Ito; M Hamaguchi; K Isobe; N Misawa; J Asai; T Yoshida; I Nakashima
Journal:  Oncogene       Date:  1990-04       Impact factor: 9.867

9.  Peripheral neuropathies, hepatocellular carcinomas and islet cell adenomas in transgenic mice.

Authors:  A Messing; H Y Chen; R D Palmiter; R L Brinster
Journal:  Nature       Date:  1985 Aug 1-7       Impact factor: 49.962

10.  Expression of ret proto-oncogene in human neuroblastomas.

Authors:  M Nagao; Y Ishizaka; A Nakagawara; K Kohno; M Kuwano; T Tahira; F Itoh; I Ikeda; T Sugimura
Journal:  Jpn J Cancer Res       Date:  1990-04
View more
  8 in total

1.  Targeted expression of MYCN causes neuroblastoma in transgenic mice.

Authors:  W A Weiss; K Aldape; G Mohapatra; B G Feuerstein; J M Bishop
Journal:  EMBO J       Date:  1997-06-02       Impact factor: 11.598

2.  No mutations found by RET mutation scanning in sporadic and hereditary neuroblastoma.

Authors:  R M Hofstra; N C Cheng; C Hansen; R P Stulp; T Stelwagen; N Clausen; N Tommerup; H Caron; A Westerveld; R Versteeg; C H Buys
Journal:  Hum Genet       Date:  1996-03       Impact factor: 4.132

3.  Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B.

Authors:  K M Carlson; S Dou; D Chi; N Scavarda; K Toshima; C E Jackson; S A Wells; P J Goodfellow; H Donis-Keller
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

4.  The multikinase inhibitor RXDX-105 is effective against neuroblastoma in vitro and in vivo.

Authors:  Sean M Flynn; Jacqueline Lesperance; Andrew Macias; Nikki Phanhthilath; Megan Rose Paul; Jong Wook Kim; Pablo Tamayo; Peter E Zage
Journal:  Oncotarget       Date:  2019-10-29

5.  Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways.

Authors:  Divya Subramonian; Nikki Phanhthilath; Hannah Rinehardt; Sean Flynn; Yuchen Huo; Jing Zhang; Karen Messer; Qianxing Mo; Shixia Huang; Jacqueline Lesperance; Peter E Zage
Journal:  Br J Cancer       Date:  2020-05-27       Impact factor: 7.640

Review 6.  Systematic review of the receptor tyrosine kinase superfamily in neuroblastoma pathophysiology.

Authors:  Esteban Javier Rozen; Jason Matthew Shohet
Journal:  Cancer Metastasis Rev       Date:  2021-10-30       Impact factor: 9.264

7.  Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma.

Authors:  Bradley D DeNardo; Michael P Holloway; Qinqin Ji; Kevin T Nguyen; Yan Cheng; Marcus B Valentine; Arthur Salomon; Rachel A Altura
Journal:  PLoS One       Date:  2013-12-11       Impact factor: 3.240

Review 8.  Cell Proliferation in Neuroblastoma.

Authors:  Laura L Stafman; Elizabeth A Beierle
Journal:  Cancers (Basel)       Date:  2016-01-12       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.